Development and Bio-Predictive Evaluation of Biopharmaceutical Properties of Sustained-Release Tablets with a Novel GPR40 Agonist for a First-in-Human Clinical Trial

• المؤلفون الرئيسيون: Ewelina Juszczyk (مؤلف), Kamil Kisło (مؤلف), Paweł Żero (مؤلف), Ewa Tratkiewicz (مؤلف), Maciej Wieczorek (مؤلف), Jadwiga Paszkowska (مؤلف), Grzegorz Banach (مؤلف), Marcela Wiater (مؤلف), Dagmara Hoc (مؤلف), Grzegorz Garbacz (مؤلف), Jaroslaw Sczodrok (مؤلف), Dorota Danielak (مؤلف)
• التنسيق: كتاب
• منشور في: MDPI AG, 2021-05-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Sustained-release (SR) formulations may appear advantageous in first-in-human (FIH) study of innovative medicines. The newly developed SR matrix tablets require prolonged maintenance of API concentration in plasma and should be reliably assessed for the risk of uncontrolled release of the drug. In t...